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Ferric peroxoanionCYP106A1 from Bacillus megaterium DSM319 was recently shown to catalyze steroid and terpene
hydroxylations. Besides producing hydroxylated steroid metabolites at positions 6b, 7b, 9a and
15b, the enzyme displayed previously unknown 11-oxidase activity towards 11b-hydroxysteroids.
Novel examples for 11-oxidation were identiﬁed and conﬁrmed by 1H and 13C NMR for prednisolone,
dexamethasone and 11b-hydroxyandrostenedione. However, only 11b-hydroxyandrostenedione
formed a single 11-keto product. The latter reaction was chosen to investigate the kinetic solvent
isotope effect on the steady-state turnover of the CYP106A1-mediated 11-oxidation. Our results
reveal a large inverse kinetic isotope effect (0.44) suggesting the involvement of the ferric
peroxoanion as a reactive intermediate.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The CYP106A1 enzyme from Bacillus megaterium DSM319 was
recently isolated and characterized by our group [11]. Its closest
homologue, CYP106A2 from B. megaterium ATCC13368 has been
extensively investigated and recognized as a highly potent catalyst
for both steroid and terpene hydroxylations [5,8,9,37,50]. Based on
the 63% amino acid sequence identity between the subfamily
members, the functional characterization of CYP106A1 concerning
tri-terpene hydroxylation [11], followed by the investigation of
steroid hormone transformation [22,24] was performed. We have
demonstrated the 6b, 7b, 9a and 15b steroid-hydroxylase activity
of CYP106A1, in addition to the 11-oxidation of corticosterone
and cortisol [22]. The latter reaction was also observed for the
human CYP11B1, converting cortisol to cortisone [41]; however,
the reaction mechanism has never been investigated. Since such
11-oxo steroid formation is uncommon in P450 catalysis, we wereinterested in studying the underlying mechanism by evaluating
the kinetic solvent isotope effect (KSIE) in the CYP106A1-
mediated 11-oxidation. The effect of hydrogen substitution by deu-
terium on the catalytic activity provides valuable information on
proton involvement in the P450 catalytic steps.
The catalytic cycle of a P450 (Fig. 1), based on CYP101 [14,28],
starts with the ferric resting state of the enzyme (1) [32,33].
Upon substrate binding, the six-coordinated low-spin complex is
shifted to the ﬁve-coordinated high-spin state (2) and an electron
transfer from an associated redox partner takes place (3) [39,43].
On subsequent binding of a molecular oxygen, the oxy-ferrous
state (4) is formed [13,27], which is then reduced to a ferric perox-
oanion (5a) leading to the formation of a hydroperoxo intermedi-
ate (5b), compound 0 (Cpd 0), on acceptance of a proton [20].
The availability of a second proton causes the release of a water
molecule and generates compound I (Cpd I) (6) [19,35].
Subsequently, the product is released (7) regenerating the ferric
heme, thus allowing the next catalytic cycle to begin.
Alternatively, the activated oxygen can be released through one
of the ‘‘uncoupling’’ pathways (shunts, depicted in dashed grey in
Fig. 1), which can abort the catalytic cycle, being unproductive
regarding substrate oxidation, yet still consuming pyridine nucleo-
tide, NADP(H)/NADH.
In general, standard P450-mediated reactions (e.g. hydroxyla-
tions) are considered to proceed through the classical Cpd
Fig. 1. Cytochrome P450 catalytic cycle. The numbers (1–7) represent the actual state of the enzyme: 1 – Low-spin substrate-free state. 2 – High-spin enzyme-substrate
complex. 3 – High-spin ferrous state. 4 – Oxy-ferrous state. 5a – Ferric peroxo intermediate. 5b – Ferric hydroperoxo intermediate/compound 0. 6 – High-valent iron-oxo
state/compound I. 7 – Product oxidation and release. RH and ROH illustrate the substrate and the product, respectively. The three unproductive shunt-pathways are marked
with dashed grey arrows and the reduced oxygen products are shown as outlets. (The cycle has been adapted from Makris et al. [28] and Denisov et al. [14].)
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place with the help of two consecutive proton uptakes
[3,19,25,47]. However, the ferric peroxoanion (5a) can also inter-
vene in the P450 catalysis, which has recently been observed in
the CYP17A1-mediated lyase reaction [18].
In this study, we investigated the underlying reaction mecha-
nism of the CYP106A1-mediated 11-oxidation which has recently
been described using corticosterone and cortisol as substrates
[22]. Both steroid conversions displayed several hydroxy-
derivatives in addition to the 11-keto-product. Therefore, further
11b-hydroxysteroid analogs were screened to obtain a
regio-selective C11-oxidation. The chosen steroids, prednisolone,
dexamethasone and 11b-hydroxyandrostenedione (11-OH-AD),
were previously identiﬁed as high-spin-shift-inducing CYP106A1
substrates, yet, the reactions were not investigated in detail and
the products were not characterized [22]. At ﬁrst, we performed
in vitro transformation of the substrates, followed by their
in vivo turnover using a CYP106A1-based B. megaterium
whole-cell system to obtain higher product yields required for
the structural elucidation by nuclear magnetic resonance (NMR).
The product structures conﬁrmed the 11-oxidation of all
substrates; however, only the 11-OH-AD conversion led to a
single 11-keto-product, whereas prednisolone and dexamethasone
displayed several hydroxy-metabolites as well. As a result, the
regio-selective 11-oxidation of 11-OH-AD was chosen to
study the reaction mechanism employing the KSIE, a proven
method to distinguish the involvement of P450 reaction intermedi-
ates Cpd I or the ferric peroxoanion during P450 catalysis
[1,18,21,31,38,47,49].2. Materials and methods
2.1. Protein expression and puriﬁcation
The expression and puriﬁcation of the CYP106A1 enzyme was
performed as described elsewhere [11]. The truncated bovine
adrenodoxin (Adx4–108) and the bovine adrenodoxin reductase
(AdR) were expressed and puriﬁed as described by Uhlmann
et al. [45] and Sagara et al. [36], respectively.
2.2. In vitro conversion and steady state kinetic turnover
Prednisolone, dexamethasone and 11-OH-AD were converted
with a reconstituted system containing the CYP106A1 enzyme,
AdR and Adx4–108 (in a ratio of 1:2:20), and a NADPH regenerating
system, as formerly described by Kiss et al. [22]. The reaction was
performed at 30 C, for 60 min using 200 lM substrate. The ﬁnal
CYP106A1 concentration was 2 lM in the case of 11-OH-AD and
5 lM for both prednisolone and dexamethasone.
The steady state kinetic turnover of 11-OH-AD was performed
in protiated and deuterated solvent systems using 2 lM enzyme
and 50 lM ﬁnal substrate concentration. To investigate the effect
of radical scavengers on the catalytic rate, the in vitro conversions
were performed with the addition of ascorbate (20 mM), catalase
(20 U) and superoxide-dismutase (SOD) (3 U), individually as well
as in combination. To determine whether hydrogen peroxide
(H2O2) could be applied to reconstitute the activity of CYP106A1,
H2O2 and cumene hydroperoxide were used in a ﬁnal concentra-
tion of 50 lM. The reactions were stopped after 20 min and
Fig. 2. HPLC chromatograms of the CYP106A1 catalyzed prednisolone conversion.
(A) Negative control, containing prednisolone only. (B) In vitro prednisolone
conversion, using bovine Adx4–108 (100 lM), bovine AdR (10 lM) and CYP106A1
(5 lM). (C) In vivo conversion of prednisolone using the CYP106A1-overexpressing
B. megaterium MS941 strain.
Fig. 3. HPLC chromatograms of the CYP106A1-catalyzed dexamethasone conver-
sion. (A) Negative control, containing dexamethasone only. (B) In vitro dexam-
ethasone conversion, using bovine Adx4–108 (100 lM), bovine AdR (10 lM) and
CYP106A1 (5 lM). (C) In vivo conversion of dexamethasone using the CYP106A1-
overexpressing B. megaterium MS941 strain.
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ing the organic phases, the dried samples were dissolved in metha-
nol and subjected to high-performance liquid chromatography
(HPLC) analysis. An ec MN Nucleodur C18 (3 lM, 4.0  125 mm)
column was used, with a mobile phase consisting of methanol,
tetrahydrofuran and water in an 8:19:72 ratio. The steroids were
eluted in an isocratic mode with a ﬂow rate of 0.5 mL/min and
detected at 240 nm. The conversions were analyzed using the
peak areas (area%) of the HPLC chromatograms with the help of
the ChromPass/Galaxie Chromatography Data System (Jasco,
Gross-Umstadt, Germany).
2.3. In vivo conversion and product puriﬁcation
The CYP106A1-based B. megaterium whole-cell system (harbor-
ing the plasmid pSMF2.1B) was used for biotransformation as
described earlier [11,22]. The substrate was added in a ﬁnal con-
centration of 400 lM to the B. megaterium resting cells in
100 mM potassium phosphate buffer (pH 7.4). The reaction was
stopped after 24 h and extracted twice with ethyl acetate. The
samples were dried and resuspended in the HPLC mobile phase.
The product puriﬁcation was performed with a preparative HPLC
column (ec MN Nucleodur C18 VP (5 lM, 8  250 mm) using
gradient elution (solvent A: 10% acetonitrile (ACN), solvent B:
100% ACN) with a ﬂow rate of 2 mL/min.
2.4. NMR characterization of the metabolites
The NMR spectra were recorded in CD3OD or in CDCl3 with a
Bruker DRX 500 or a Bruker Avance 500 NMR spectrometer at
300 K. The chemical shifts were relative to CH3OD at d 3.30 (1H
NMR) and CD3OD at d 49.00 (13C NMR) or to CHCl3 at d 7.26 (1H
NMR) and CDCl3 at d 77.00 (13C NMR) respectively, using the stan-
dard d notation in parts per million. The 1D NMR (1H and 13C NMR,
DEPT135) and the 2D NMR spectra (gs-HH-COSY, gs-NOESY,
gs-HSQCED, and gs-HMBC) were recorded using the BRUKER pulse
program library. All assignments were based on extensive NMR
spectral evidence. For the detailed NMR data of the identiﬁed prod-
ucts see Supplementary Material.
3. Results and discussion
3.1. Substrate conversions, product puriﬁcation and characterization
by NMR
Since the previously identiﬁed substrates for the CYP106A1
11-oxidation (corticosterone and cortisol) gave rise to multiple
product formation [22], other 11b-hydroxysteroid analogs were
investigated to identify a selective 11-keto product formation.
The in vitro conversion of the pharmaceutically relevant glucocor-
ticoids, prednisolone and dexamethasone, also resulted in several
products (Table 1, Figs. 2B and 3B) in contrast to the transforma-
tion of 11-OH-AD, where only a single product was formed with
a yield of 50% (Table 1, Fig. 4B).Table 1
In vitro conversion results showing relative conversion and product retention times,
when applicable.
Substrate (RT/min) RC (%) Product RT (min) Remark
P1 P2 P3 P4
Prednisolone (10.5) 33 3.6 4.8 8.4 – Fig. 2B
Dexamethasone (20.4) 40 5.1 6.9 8.3 15.8 Fig. 3B
11-OH-AD (13.0) 50 10.5 – – – Fig. 4B
RT, retention time; RC, relative conversion.Even though single product formation was only observed with
11-OH-AD, we were interested in characterizing all
11b-hydroxysteroid metabolites by NMR, to identify novel
11-keto products and other glucocorticoid derivatives of potential
pharmaceutical value. For the isolation and puriﬁcation of the reac-
tion products, the steroid bioconversions were performed via a
CYP106A1-based B. megaterium whole-cell system.
The in vivo turnover of prednisolone led to 51% conversion
resulting in a main product, P1 (35%) with identical retention time
(3.6 min) to the one observed in vitro. Besides the major product,
multiple side-products (<5%) were also detected, out of which P2
(4.8 min) and P3 (8.3 min) eluted at the same time as the
respective in vitro metabolites (Fig. 2B and C). Although both P1
Fig. 4. HPLC chromatograms of the CYP106A1 catalyzed 11b-hydroxyandrostene-
dione conversion. (A) Negative control, containing 11-OH-AD only. (B) In vitro 11-
OH-AD conversion, using bovine Adx4–108 (40 lM), bovine AdR (4 lM) and
CYP106A1 (2 lM). (C) In vivo conversion of 11-OH-AD using the CYP106A1-
overexpressing B. megaterium MS941 strain.
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sis of their puriﬁed fractions showed a mixture of several steroids,
containing 15b-hydroxyprednisolone as a major compound.
Likewise, product P3, which was identiﬁed as a 2:3 mixture of
15b-hydroxyprednisone and 1,2-dihydro-15b-hydroxyprednisone
displaying 11-oxidation catalyzed by CYP106A1 (Scheme 1). The
unusual 1(2)-double bond hydrogenation has not been observed
in our previous studies [22], hence, it was proposed to be the result
of an uncharacterized enzyme present in the B. megateriumMS941
strain. It has been reported that 3-ketosteroid-dehydrogenases
present in Nocardia, Mycobacterium and Actinobacter sp. can be
responsible for both 1(2)-hydrogenase and reductase reactions
[2,17,46]. However, these enzymes have not been described so
far for B. megaterium. Therefore, the origin of the
1(2)-hydrogenase reaction remains unclear. The above described
prednisolone metabolites were previously unidentiﬁed, and
therefore, no biotechnological applications are known to date.
Nonetheless, the 15b-hydroxyl group attached to both pred-
nisolone and prednisone structures provides a new reaction siteScheme 1. Oxidative transformation of pfor further functionalization, contributing to the development of
novel glucocorticoids possessing anti-inﬂammatory/immunomodu
latory activity with a potentially reduced risk of side effects.
Using the CYP106A1-based whole-cell system, nearly 50% of
dexamethasone was converted in 24 h, yielding four products, P1
to P4, which were all successfully isolated and characterized.
Each of the identiﬁed metabolites showed identical retention times
to the ones observed in vitro, eluting at 5.1, 6.9, 8.3 and 15.8 min,
respectively (Fig. 3B and C). The major product, P1 (37%), and P2
(6%) were identiﬁed as 15b-hydroxy- and 6b-hydroxy-derivatives
of dexamethasone, respectively. The latter one also known as the
major human metabolite of dexamethasone produced by CYP3A4
[16,30,42]. Besides the hydroxylated derivatives, two minor
11-oxidized compounds were observed and characterized as
11-ketodexamethasone (P4, 2%) and 15b-hydroxy-11-ketodexame
thasone (P3, 3%) (Scheme 2). The 11-keto compound was previ-
ously identiﬁed as a speciﬁc glucocorticoid receptor agonist,
explaining the glucocorticoid effect of dexamethasone in tissues
expressing the 11b-hydroxysteroid dehydrogenase type 2 enzyme,
responsible for 11-oxidation in mammalian tissues [34].
The in vivo turnover of 11-OH-AD resulted in 90% conversion
within 24 h and a single main product along with traces of minor
side products, which were not observed in the in vitro system
(Fig. 4C). The major product, P1 (10.5 min), showed identical
retention time to that of the in vitro reaction (Fig. 4B). The NMR
characterization identiﬁed P1 as the 11-keto derivative, adrenos-
terone, supporting the previously observed 11-oxidase activity of
CYP106A1 during the transformation of corticosterone and cortisol
[22] (Scheme 3). Adrenosterone is a weak androgen hormone
found only in trace amounts in mammals, but in higher quantities
in ﬁsh, where it acts as a precursor of 11-ketotestosterone, the
endogenous androgenic sex hormone [7,10]. It is sold as a dietary
supplement, reducing body fat and increasing muscle mass and
was also proposed to be a selective inhibitor of
11b-hydroxysteroid dehydrogenase type I enzyme [12].
3.2. Steady state kinetic turnover in protiated and deuterated solvent
systems
The CYP106A1-mediated conversion of prednisolone and
dexamethasone resulted in multiple products, in contrast to
11-OH-AD, where only the 11-keto product formation was
detected. Thus, the latter reaction was chosen as a suitable model
for the investigation of KSIE in CYP106A1-mediated 11-oxidation.rednisolone catalyzed by CYP106A1.
Scheme 2. Oxidative transformation of dexamethasone catalyzed by CYP106A1.
Scheme 3. 11-Oxidation of 11b-hydroxyandrostenedione catalyzed by CYP106A1.
2324 F.M. Kiss et al. / FEBS Letters 589 (2015) 2320–2326The steady state turnover of 11-OH-AD by CYP106A1 was inves-
tigated with a time-dependent reaction in the presence of saturat-
ing substrate concentration. To study the catalytic activity, an
incubation time of 20 min was chosen, representing the linear
phase of the reaction (Fig. 5A). The turnover was carried out in a
protiated buffer system, in which an individual rate of
adrenosterone formation of 0.36 ± 0.04 min1 was observed.
Interestingly, upon H2O substitution for D2O, the conversion
demonstrated a signiﬁcantly increased catalytic rate of
0.81 ± 0.03 min1, leading to a 2.25-times faster product formation
upon H/D exchange. These rates correspond to an inverse KSIE
(kH/kD) of 0.44 (Fig. 5B) suggesting that the 11-oxidation reaction
is mediated through the unprotonated ferric peroxo intermediate,
in contrast to traditional hydroxylation reactions, which are
believed to proceed through the classical Groves rebound mecha-
nism with Cpd I as the reactive intermediate [3,19,25,47]. The
detected large inverse KSIE could be explained by the fact that
inhibiting protonation of the peroxo-ferric species in deuterated
solvents facilitates the productive oxidation rather than the uncou-
pling via proton-dependent unproductive pathways (peroxide
shunt, oxidase shunt). Forming the nucleophilic peroxoanion inter-
mediate (Fig. 1, (5a)) does not involve any protonation event, thus
the catalytic activity would be expected to be the same in both H2O
and D2O buffer systems. However, the slower rate of Cpd I forma-
tion in a deuterated solvent system in combination with inhibited
unproductive pathways could result in the increase of the perox-
oanion intermediate, along with the product formation [18]. The
latter was described for tyrosine hydroxylase [15] and putida-
monooxin [44], where, as a result of the slower rate of uncoupling
reactions compared with the productive pathway in D2O, a large
inverse KSIE was observed. Concerning P450 enzymes, theinvolvement of the ferric peroxoanion has only been observed for
the CYP17-catalyzed C17-C20 lyase reaction [18], its involvement
in an oxidase reaction has not been demonstrated so far.
To exclude the role of unproductive pathways and the possible
H2O2-mediated substrate oxidation (reverse peroxide shunt) and
to support the participation of the ferric peroxo species in the
CYP106A1-catalyzed 11-oxidation, the in vitro conversions were
performed with the addition of radical scavengers and in the pres-
ence of H2O2 or cumene hydroperoxide. As scavenging agents
ascorbate (neutralizing the superoxide radical, singlet oxygen
and hydroxyl radicals), catalase (decomposing hydrogen peroxide
to water and oxygen) and superoxide dismutase (SOD) (scavenger
of superoxide anion) were applied, individually or in combination.
No signiﬁcant decrease in the catalytic rate was observed in
comparison to the positive control, the 11-OH-AD conversion
in protiated environment (Fig. 5C). Using H2O2 or cumene
hydroperoxide (CHP), no product formation was detected.
These results suggest that the previously observed inverse KSIE is
not the result of an inhibited uncoupling reaction but of the
catalysis via a proton-independent intermediate. Since steroid
11-dehydrogenation by a P450 had never been investigated
before, similar P450 dependent keto-product formations described
in the literature have been considered for possible parallels.
Interestingly, in contrast to our observations, the microsomal oxi-
dation of cyclohex-2-en-1-ol [4], the CYP3A11 mediated
hydroxy-D8-tetrahydrocannabinol transformation [29] and the
CYP2E1-catalyzed ethanol oxidation [48] were all proposed to pro-
ceed through the gem-diol or the combination of gem-diol and
double hydrogen abstraction pathways involving Cpd I (Fig. 1,
(6)) as a reactive intermediate. However, the observed inverse
KSIE and the absent role of proton-dependent uncoupling
Fig. 5. Investigation of the catalytic rate of 11-oxidation by CYP106A1. (A) Time dependent conversion of 11-OH-AD using CYP106A1 (2 lM) and 11-OH-AD (50 lM). (B)
Steady-state kinetic solvent isotope effects observed for 11-oxidase CYP106A1 catalysis. The numbers inside the bars indicate the catalytic activity, while the error bars
represent the standard deviation of 5 independent reactions. (C) The effect of radical scavengers on the catalytic rate of 11-OH-AD oxidation. The error bars represent the
standard deviation of 3 independent measurements. *SOD, superoxide-dismutase; RSC, radical scavengers in combination; CHP, cumene hydroperoxide.
Scheme 4. Proposed model for the 11-oxidation of 11-OH-AD by CYP106A1. The 11-oxidation proceeds through a nucleophilic attack at the C11 hydroxyl group of 11-OH-AD
(A) by the ferric peroxo species. A subsequent hydroxylation step leads to the ‘gem-diol’ (B). The ‘gem-diol’ undergoes a dehydration reaction, abstracting the hydrogen and
forming the 11-keto product, adrenosterone (C).
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reconcilable with a proton-dependent, Cpd I-mediated mechanism.
Therefore, we propose that the 11-oxidation reaction of 11-OH-AD
is mediated by a nucleophilic attack of the ferric peroxoanion, as
illustrated in Scheme 4. To provide additional evidence for the
involvement of the ferric peroxo species, the spectroscopic
characterization of the reactive intermediate could be a topic of
further research, as reviewed elsewhere [23,26,40].
In conclusion, we present prednisolone, dexamethasone and
11-OH-AD as novel substrates for the 11-oxidation by CYP106A1.
The enzyme performed selective 11-oxidation on 11-OH-AD,
resulting in a single 11-keto product, while the conversion of pred-
nisolone and dexamethasone displayed 6b- and 15b-hydroxylated
derivatives, as well as the 11-keto steroids. Since the hydroxy
metabolites can be developed into functionalized drugs with
improved properties (e.g.: higher speciﬁcity, improved pharma-
cokinetics) [6], the production of such novel derivatives using
CYP106A1 is considered a promising approach for the pharmaceu-
tical industry. In addition, due to the selective conversion of
11-OH-AD, the 11-oxidation mechanism was also investigated.
We observed an inverse KSIE (0.44), suggesting that the
11-oxidation takes place without the involvement of proton
uptake, proposing for the ﬁrst time the ferric peroxoanion as a
reactive intermediate in a P450-mediated oxidation reaction.
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